Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Financing

Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives

Restructuring Edition: Financial market conditions are improving, but gains have not stopped some companies from cutting costs or shutting down. MEI may wind down if it does not identify another strategic alternative and Aslan has begun to liquidate, while others have cut jobs.

Restructuring Business Strategies

Wegovy And M&A Deals Help Novo Holdings Expand Biotech Investments

Flush with cash, the controlling stakeholder of Novo Nordisk’s life sciences investment arm is increasing its financing of other biopharma innovators.

Companies Financing

Lucky No. 13? Artiva Goes Public, Rises In First Day Of Trading

Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.

Financing Growth

Finance Watch: NGM Reemerges With $122m During Post-July 4th VC Mega-Round Boom

Private Company Edition: After its acquisition by an investor earlier this year, NGM Bio has raised a $122m series A round, adding to a recent surge in large venture capital financings. Also, Vanqua Bio disclosed $45m in new funding and Renalys completed a $38.4m series A.

Financing Growth

Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs

The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.

Financing Cardiovascular

Scorpion Sinks Pincers Into Funding Round For PI3K Inhibitor

The oncology-focused start-up announced it closed a $150m series C financing that it plans to use to advance STX-478.

Financing Business Strategies

The IPO Queue Fills Up, But A Recovery Is A Way Off

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Financing Commercial

ASCO Data Are Catalyst For CatalYm Cash Boost

The German biotech has unveiled a $150m series D financing round to support a “broad Phase IIb development program for visugromab” and explore its potential to induce cancer remission depth and durability across multiple solid tumor indications.

Financing ImmunoOncology

Investors Back Asceneuron To Rival Lilly In Alzheimer’s Oral Drug Class

The Switzerland-based company is ready to begin a Phase II study with a novel OGA inhibitor after raising $100m from a consortium of investors.

Commercial Companies

Finance Watch: US Market May Warm To Go-Public Options As Summer Progresses

Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.

Financing Business Strategies

Destiny Joins AIM Exodus In Bid To Stay Afloat

Chairman Sir Nigel Rudd said re-registering as a private company is necessary to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials, without which “liquidation of the company is the most likely alternative.”

Business Strategies Infectious Diseases

IPOs Collapse In The Second Quarter

Biotechs have had a difficult time raising cash through flotations over the past quarter, with one stepping away altogether.

Financing Business Strategies
See All